Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 21, 2026, 11:07 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 26 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Atypical Lobular Hyperplasia Clear all
Active, not recruiting Not applicable Interventional Accepts healthy volunteers
View directory record Official record
Conditions
Atypical Hyperplasia of the Breast, Lobular Breast Carcinoma In Situ, Pleomorphic Lobular Breast Carcinoma In Situ
Interventions
Cancer Educational Materials, Decision Aid, Interview, Questionnaire Administration
Behavioral · Other
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
Not listed
Enrollment
412 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2028
U.S. locations
96
States / cities
Antioch, California • Costa Mesa, California • Duarte, California + 67 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced May 21, 2026, 11:07 PM EDT
Terminated Not applicable Interventional Results available
View directory record Official record
Conditions
Atypical Ductal Hyperplasia
Interventions
Contrast enhanced mammography
Device
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
30 Years and older · Female only
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 10, 2020 · Synced May 21, 2026, 11:07 PM EDT
Active, not recruiting Phase 3 Interventional Results available
View directory record Official record
Conditions
Atypical Ductal Breast Hyperplasia, BRCA1 Mutation Carrier, BRCA2 Mutation Carrier, Ductal Breast Carcinoma in Situ, Lobular Breast Carcinoma in Situ
Interventions
metformin hydrochloride, placebo
Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
25 Years to 55 Years · Female only
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2026
U.S. locations
27
States / cities
Duarte, California • Los Angeles, California • South Pasadena, California + 18 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced May 21, 2026, 11:07 PM EDT
Not listed No phase listed Observational
View directory record Official record
Conditions
Breast Cancer
Interventions
Not listed
Lead sponsor
New York Presbyterian Hospital
Other
Eligibility
18 Years and older · Female only
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1991
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 17, 2009 · Synced May 21, 2026, 11:07 PM EDT
Completed Not applicable Interventional
View directory record Official record
Conditions
Atypical Ductal Breast Hyperplasia, Atypical Lobular Breast Hyperplasia, BRCA1 Mutation Carrier, BRCA2 Mutation Carrier, Ductal Breast Carcinoma in Situ, Lobular Breast Carcinoma in Situ
Interventions
counseling intervention, behavioral dietary intervention, exercise intervention, questionnaire administration, laboratory biomarker analysis
Other · Behavioral
Lead sponsor
University of Washington
Other
Eligibility
35 Years to 65 Years · Female only
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2013
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 19, 2016 · Synced May 21, 2026, 11:07 PM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers
View directory record Official record
Conditions
Breast Atypical Hyperplasia, Breast Carcinoma, Breast Ductal Carcinoma In Situ, Breast Lobular Carcinoma In Situ
Interventions
Biospecimen Collection, Mammography, Omega-3-Acid Ethyl Esters, Questionnaire Administration, Random Periareolar Fine-Needle Aspiration, Tamoxifen
Procedure · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
45 Years to 74 Years · Female only
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
3
States / cities
Kansas City, Kansas • Ann Arbor, Michigan • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced May 21, 2026, 11:07 PM EDT
Completed Phase 2 Interventional
View directory record Official record
Conditions
Ductal Carcinoma In Situ, Atypical Lobular Hyperplasia, Atypical Ductal Hyperplasia, Lobular Carcinoma In Situ
Interventions
Ruxolitinib, Placebo (for Ruxolitinib)
Drug
Lead sponsor
Julie Nangia
Other
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
8
States / cities
Birmingham, Alabama • Indianapolis, Indiana • The Bronx, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced May 21, 2026, 11:07 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers
View directory record Official record
Conditions
Breast Cancer
Interventions
RealRisks
Behavioral
Lead sponsor
Columbia University
Other
Eligibility
35 Years to 74 Years · Female only
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 10, 2026 · Synced May 21, 2026, 11:07 PM EDT
Completed No phase listed Observational
View directory record Official record
Conditions
Atypical Ductal Hyperplasia (ADH) of the Breast
Interventions
Not listed
Lead sponsor
Yale University
Other
Eligibility
40 Years and older · Female only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 27, 2019 · Synced May 21, 2026, 11:07 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers
View directory record Official record
Conditions
Atypical Lobular Hyperplasia, Atypical Ductal Hyperplasia, Lobular Carcinoma in Situ
Interventions
Molecular Breast Imaging, Screening Mammography
Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2015
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 9, 2016 · Synced May 21, 2026, 11:07 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers
View directory record Official record
Conditions
Atypical Ductal Breast Hyperplasia, Breast Cancer, Ductal Breast Carcinoma in Situ, Lobular Breast Carcinoma in Situ
Interventions
atorvastatin calcium, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 72 Years · Female only
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2012
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 28, 2016 · Synced May 21, 2026, 11:07 PM EDT
Terminated Phase 2 Interventional
View directory record Official record
Conditions
Breast Atypical Hyperplasia, Breast Lobular Carcinoma in Situ, Breast Atypical Lobular Hyperplasia, Breast Carcinoma
Interventions
Tamoxifen, Topical 4-OHT( 4-hydroxytamoxifen)gel 4 mg/each breast/day, Placebo, Questionnaire Administration
Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 80 Years · Female only
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
3
States / cities
Evanston, Illinois • Rochester, Minnesota • Camden, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced May 21, 2026, 11:07 PM EDT
Completed Not applicable Interventional
View directory record Official record
Conditions
Breast Cancer, Precancerous Condition
Interventions
omega-3 fatty acid, placebo
Dietary Supplement · Other
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
21 Years to 120 Years · Female only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
2
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 26, 2017 · Synced May 21, 2026, 11:07 PM EDT
Not yet recruiting Phase 2 Interventional
View directory record Official record
Conditions
Breast Cancer, Ductal Carcinoma, Estrogen-receptor-positive Breast Cancer, Atypical Lobular Hyperplasia, BRCA2 Mutation, CHEK2 Gene Mutation, Ataxia Telangiectasia Mutated Gene Mutation
Interventions
Exemestane, Tamoxifen
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
Female only
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 29, 2026 · Synced May 21, 2026, 11:07 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Breast Cancer, Precancerous Condition
Interventions
broccoli sprout extract, placebo
Dietary Supplement · Other
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
21 Years to 120 Years · Female only
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 26, 2017 · Synced May 21, 2026, 11:07 PM EDT
Recruiting No phase listed Observational
View directory record Official record
Conditions
Breast Atypical Ductal Hyperplasia, Breast Atypical Lobular Hyperplasia, Breast Carcinoma, Breast Lobular Carcinoma In Situ, Breast Sclerosing Adenosis
Interventions
Follow-Up, Physical Examination, Questionnaire Administration
Procedure · Other
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
960 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2035
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 5, 2025 · Synced May 21, 2026, 11:07 PM EDT
Completed No phase listed Observational
View directory record Official record
Conditions
Breast Neoplasms
Interventions
Not listed
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
20 Years and older · Female only
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2012
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 30, 2017 · Synced May 21, 2026, 11:07 PM EDT
Completed No phase listed Observational
View directory record Official record
Conditions
Breast Cancer, Precancerous Condition
Interventions
medical chart review, questionnaire administration, study of socioeconomic and demographic variables, Excess human biological tissue, quality-of-life assessment
Other · Procedure
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years to 120 Years
Enrollment
4,945 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2016
U.S. locations
65
States / cities
Colorado Springs, Colorado • Denver, Colorado • Lakewood, Colorado + 46 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2023 · Synced May 21, 2026, 11:07 PM EDT
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
Breast Atypical Ductal Hyperplasia, Breast Atypical Lobular Hyperplasia, Breast Carcinoma, Breast Ductal Carcinoma In Situ, Breast Lobular Carcinoma In Situ, Estrogen Receptor-Positive Breast Carcinoma
Interventions
Biopsy Procedure, Biospecimen Collection, Mammography, Questionnaire Administration, Tamoxifen
Procedure · Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 55 Years · Female only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
11
States / cities
Tucson, Arizona • Chicago, Illinois • Kansas City, Kansas + 6 more
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced May 21, 2026, 11:07 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers
View directory record Official record
Conditions
Atypical Ductal Breast Hyperplasia, Lobular Carcinoma in Situ (LCIS), Atypical Lobular Hyperplasia (ALH) of Breast
Interventions
SOM 230 / Pasireotide
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
21 Years and older · Female only
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 4, 2016 · Synced May 21, 2026, 11:07 PM EDT
Terminated Not applicable Interventional
View directory record Official record
Conditions
Breast Cancer, Precancerous Condition
Interventions
Ground Flaxseed, No Intervention
Dietary Supplement · Other
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
21 Years to 50 Years · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
2
States / cities
Chicago, Illinois • Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jun 2, 2016 · Synced May 21, 2026, 11:07 PM EDT
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
Breast Atypical Hyperplasia, Breast Carcinoma, Breast Ductal Carcinoma In Situ, Breast Lobular Carcinoma In Situ
Interventions
Acolbifene Hydrochloride, Biospecimen Collection, Mammography, Questionnaire Administration, Random Periareolar Fine-Needle Aspiration, Tamoxifen
Drug · Procedure · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
35 Years and older · Female only
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
4
States / cities
Duarte, California • Chicago, Illinois • Kansas City, Kansas + 1 more
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced May 21, 2026, 11:07 PM EDT
Terminated No phase listed Observational
View directory record Official record
Conditions
Breast Atypical Ductal Hyperplasia, Breast Atypical Lobular Hyperplasia, Breast Carcinoma, Breast Lobular Carcinoma In Situ
Interventions
Biospecimen Collection, Genotyping, Survey Administration
Procedure · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
30 Years to 75 Years · Female only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced May 21, 2026, 11:07 PM EDT
Completed Not applicable Interventional
View directory record Official record
Conditions
Atypical Ductal Breast Hyperplasia, BRCA1 Gene Mutation, BRCA2 Gene Mutation, Ductal Breast Carcinoma in Situ, Lobular Breast Carcinoma in Situ
Interventions
curcumin, Biomarker analysis, Assessment of Dietary Intake, Daily Log
Dietary Supplement · Other
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
19 Years and older · Female only
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 29, 2019 · Synced May 21, 2026, 11:07 PM EDT